Abbott Laboratories (NYSE:ABT) Reaches New 1-Year Low – Should You Sell?

Abbott Laboratories (NYSE:ABT)’s stock price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $90.29 and last traded at $90.4260, with a volume of 3130490 shares. The stock had previously closed at $91.33.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. The Goldman Sachs Group cut their target price on shares of Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Jefferies Financial Group lowered their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Citigroup dropped their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Mizuho decreased their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Finally, Raymond James Financial lowered their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Stock Performance

The stock has a market capitalization of $155.90 billion, a PE ratio of 25.07, a PEG ratio of 1.51 and a beta of 0.66. The business’s 50 day moving average is $104.33 and its 200 day moving average is $116.20. The company has a current ratio of 1.39, a quick ratio of 1.18 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the firm earned $1.09 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. Abbott Laboratories’s payout ratio is presently 70.59%.

Insider Buying and Selling

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 22,200 shares of company stock worth $2,215,100 and have sold 3,055 shares worth $353,097. Insiders own 0.46% of the company’s stock.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors have recently modified their holdings of ABT. J. Stern & Co. LLP grew its stake in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Norges Bank bought a new stake in Abbott Laboratories during the 4th quarter valued at $2,938,892,000. Invesco Ltd. lifted its holdings in shares of Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after buying an additional 4,713,135 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Abbott Laboratories by 303.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after buying an additional 3,330,368 shares in the last quarter. Finally, Ninety One UK Ltd purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at $336,815,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.